Venus Remedies’ arm bags MA approval to sell Meropenem in France

20 Aug 2013 Evaluate

Venus Pharma GmbH, a subsidiary of Venus Remedies, has made big strides in the global market by bagging marketing authorisation (MA) approval from France for Meropenem, a generic broad spectrum antibiotic injectable. It has signed a non-exclusive marketing rights deal with generic giant Mylan to sell Meropenem in France world's fifth largest pharmaceutical market with a market share of 3.8%.

Driven by its MA grants, Venus is all set to grab the maximum share in the $270-million Meropenem market in the EU in the near future. Meropenem is an off-patented generic broad spectrum anti-bacterial agent of carbapenem family, which fights diseases with a broad range of serious infections caused by single or multiple susceptible bacteria in both adults and children.

Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.

Venus Remedies Share Price

748.00 2.80 (0.38%)
08-Dec-2025 09:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1799.00
Dr. Reddys Lab 1275.90
Cipla 1513.30
Zydus Lifesciences 935.80
Lupin 2094.40
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×